3篇
您的检索式：作者名="Ahmed Reda Sayed"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Dendritic cell co-stimulatory and co-inhibitory markers in chronic HCV: An Egyptian study显示文摘AIM:To assess co-stimulatory and co-inhibitory markers of dendritic cells(DCs)in hepatitis C virus(HCV)infected subjects with and without uremia.METHODS:Three subject groups were included in the study:group 1 involved 50 control subjects,group2 involved 50 patients with chronic HCV infection and group 3 involved 50 HCV uremic subjects undergoing hemodialysis.CD83,CD86 and CD40 as co-stimulatory markers and PD-L1 as a co-inhibitory marker were assessed in peripheral blood mononuclear cells by realtime polymerase chain reaction.Interleukin-10(IL-10)and hyaluronic acid(HA)levels were also assessed.All findings were correlated with disease activity,viral load and fibrogenesis.RESULTS:There was a significant decrease in costimulatory markers;CD83,CD86 and CD40 in groups2 and 3 vs the control group.Co-stimulatory markers were significantly higher in group 3 vs group 2.There was a significant elevation in PD-L1 in both HCV groups vs the control group.PD-L1 was significantly lower in group 3 vs group 2.There was a significant elevation in IL-10 and HA levels in groups 2 and 3,where IL-10was higher in group 3 and HA was lower in group 3 vs group 2.HA level was significantly correlated with disease activity and fibrosis grade in group 2.IL-10 was significantly correlated with fibrosis grade in group 2.There were significant negative correlations between co-stimulatory markers and viral load in groups 2 and3,except CD83 in dialysis patients.There was a significant positive correlation between PD-L1 and viral load in both HCV groups.CONCLUSION:A significant decrease in DC co-stimulatory markers and a significant increase in a DC coinhibitory marker were observed in HCV subjects and to a lesser extent in dialysis patients. | Hanan Fouad Maissa Saeed El Raziky Rasha Ahmed Abdel Aziz Dina Sabry Ghada Mahmoud Abdel Aziz Manal Ewais Ahmed Reda Sayed | 2013 | World Journal of Gastroenterology2013，19，43： | 0 |
| 2 | Rationales and uncertainties for aspirin use in COVID-19:a narrative review显示文摘Objectives To review the pathophysiology of COVID-19 disease,potential aspirin targets on this pathogenesis and the potential role of aspirin in patients with COVID-19.Design Narrative review.Setting The online databases PubMed,OVID Medline and Cochrane Library were searched using relevant headlines from 1 January 2016 to 1 January 2021.International guidelines from relevant societies,journals and forums were also assessed for relevance.Participants Not applicable.Results A review of the selected literature revealed that clinical deterioration in COVID-19 is attributed to the interplay between endothelial dysfunction,coagulopathy and dysregulated inflammation.Aspirin has anti-inflammatory effects,antiplatelet aggregation,anticoagulant properties as well as pleiotropic effects on endothelial function.During the COVID-19 pandemic,low-dose aspirin is used effectively in secondary prevention of atherosclerotic cardiovascular disease,prevention of venous thromboembolism after total hip or knee replacement,prevention of pre-eclampsia and postdischarge treatment for multisystem inflammatory syndrome in children.Prehospital low-dose aspirin therapy may reduce the risk of intensive care unit admission and mechanical ventilation in hospitalised patients with COVID-19,whereas aspirin association with mortality is still debatable.Conclusion The authors recommend a low-dose aspirin regimen for primary prevention of arterial thromboembolism in patients aged 40-70 years who are at high atherosclerotic cardiovascular disease risk,or an intermediate risk with a risk-enhancer and have a low risk of bleeding.Aspirin’s protective roles in COVID-19 associated with acute lung injury,vascular thrombosis without previous cardiovascular disease and mortality need further randomised controlled trials to establish causal conclusions. | Hazem A Sayed Ahmed Eric Merrell Mansoura Ismail Anwar I Joudeh Jeffrey B Riley Ahmed Shawkat Hanan Habeb Edward Darling Reda A Goweda Mohamed H Shehata Hossam Amin Gary F Nieman Hani Aiash | 2021 | Family Medicine and Community Health2021，9，2： | 0 |
| 3 | Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity显示文摘AIM To investigate how Tregs are regulated in chronic hepatitis C virus(HCV) patients via assessment of Tregs markers(granzyme 2, CD69 and FoxP3), Teffs markers [TNFRSF4(OX40), INFG] and CD4, CD25 genes. METHODS A prospective study was conducted on 120 subjects divided into 4 groups: Group Ⅰ(n = 30) treatment na?ve chronic HCV patients; Group Ⅱ(n = 30) chronic HCV treated with Peg/Riba; Group Ⅲ(n = 30) chronic HCV associated with non-organ specific autoantibody and Group Ⅳ(n = 30) healthy persons as a control group. Tregs and Teffs markers were assessed in peripheral blood mononuclear cells by quantitative real time reverse transcriptase-polymerase chain reaction. RESULTS Chronic HCV patients exhibited significant higher levels of both Teffs and Tregs in comparison to healthy control group. Tregs markers were significantly decreased in Peg/Riba treated HCV patients in comparison to treatment na?ve HCV group. In HCV patients with antinuclear antibody(ANA) +ve, Tregs markers were significantly decreased in comparison to all other studied groups. Teffs markers were significantly elevated in all HCV groups in comparison to control and in HCV group with ANA +ve in comparison to treatment na?ve HCV group.CONCLUSION Elevated Tregs cells in chronic HCV patients dampen both CD4^+ and CD8^+ autologous T cell immune response. Interferon-α and ribavirin therapy suppress proliferation of Tregs. More significant suppression of Tregs was observed in HCV patients with autoantibodies favoring pathological autoimmune response. | Hanan Fouad Maissa El Raziky Eman Medhat Hassan Ghada Mahmoud Abdel Aziz Samar K Darweesh Ahmed Reda Sayed | 2016 | World Journal of Hepatology2016，8，30： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员